MEAI Compound's First Clinical Trial In US, Clearmind Enters NASDAQ Compliance Period
Portfolio Pulse from Lara Goldstein
Clearmind Medicine Inc. (NASDAQ:CMND) has selected Yale School of Medicine's Psychiatry Dept. as the first U.S. site for its Phase 1/2a trial on proprietary CMND-100, targeting Alcohol Use Disorder (AUD). The company has also entered a NASDAQ compliance period due to its share price falling below the minimum bid price requirement of $1.00.
May 22, 2023 | 8:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Clearmind Medicine's partnership with Yale for its Phase 1/2a trial on CMND-100 may boost investor confidence, but the company's NASDAQ compliance period could create short-term uncertainty.
Clearmind Medicine's partnership with Yale for its Phase 1/2a trial on CMND-100 may boost investor confidence in the company's drug development capabilities and potential for success. However, the company's NASDAQ compliance period due to its share price falling below the minimum bid price requirement of $1.00 creates short-term uncertainty for investors. The company has 180 days to regain compliance, which may cause fluctuations in the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100